Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HeartSciences Inc. - Warrant (NQ:HSCSW)

0.0508 -0.0142 (-21.85%)
Streaming Delayed Price Updated: 12:18 PM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HeartSciences Inc. - Warrant

< Previous 1 2 3 Next >
News headline image
Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration
Shares issued at $2.43, a 22% premium to the closing price on the purchase date, with Fortitude receiving no additional merger consideration in respect of the investment 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K
Company believes proposed Fortitude merger represents a significant opportunity for the Company’s shareholders; preliminary proxy statement in connection with the Proposed Transaction expected to be... 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences’ Patent Portfolio to More Than 45 Granted Patents
Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
Bunkerhill Health’s FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences’... 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
Agreement follows Cibolo Health’s endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences’ ECG management platform 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
Agreement with St. Vincent Health marks HeartSciences’ transition from early adopter installations to commercial SaaS deployments following the full launch of MyoVista Insights at the American College... 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
From HeartSciences Inc.
Via GlobeNewswire
News headline image
University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
From HeartSciences Inc.
Via GlobeNewswire
News headline image
Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1
Version 1.1 Designed to Provide Best Usability of any ECG System 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces Conference Participation and Investor Webinar
Virtual Events Include Investor Webinar and Presentation at Emerging Growth Conference 85 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
Patent covers estimation of measures of heart function using an ECG, which are critical in the diagnosis and early detection of heart disease 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
From Heart Test Laboratories, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.